Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MPharm Y3S2 > Mental Health Pharmacology Schizophrenia > Flashcards

Mental Health Pharmacology Schizophrenia Flashcards

1
Q

Which neurochemicals are imbalanced in the brain in SZ?

A

DA
* Glu (glutamate)
Ach, 5HT, GABA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the positive symptoms of SZ?

A

Hallucinations (auditory, visual), delusions, thought insertion, disorganised thought processes, disorganised speech, disorganised behaviour, agitation, catatonia (non response to stim)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are negative symptoms of SZ?

A

Flattening of emotional responses, low mood, loss of motivation, lack of energy, social withdrawl, anhedonia (loss of pleasurable activities), speech and language deficits, poor self care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are cognitive symptoms of SZ?

A

Impaired working memory, loss of attention, impaired decision making

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the epidemiology of SZ:

A

Prevalence 0.3-0.7%
Incidence 0.3 in 1000 so lifetime risk is 1%
Typical onset of +ve symptoms is late adolescence/ early adulthood (15-25)
Same incidence rates in male to female, but typically there is later onset in females

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the mortality like in SZ?

A

50% increased mortality
Life expectancy decreased by 20-30 years
Increases CV risk, lifestyle, suicide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the aetiology of SZ:

A

Genetic (70-80%) and environmental (20-30%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the risk factors for SZ?

A

Family history
Developmental
Environment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe how family history can be a risk factor for SZ:

A

50% concordance in identical twins
20% in non identical
10% siblings
15% parent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe how developmental factors can be a risk factor for SZ:

A

Pre-natal (before birth) factors e.g maternal stress- viral infection, birth trauma
Neurodevelopmental abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe how the environment can be a risk factor for SZ:

A

Stressful life events
Urban environment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How can genetics be a link to SZ?

A

Many SZ susceptibility genes have been identified
Involved in neuronal development, synaptic organisation and function- neurotransmission:
-receptors
-TFs
-protein turnover
-ion channels
-structural proteins
-epigenetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the pathophysiology of SZ:

A

Increase in size of ventricles
Loss of grey matter (thinning of cortex)
Decreased white matter volume
Altered activity in dorsolateral pre-frontal cortex, ventromedial pre-frontal cortex, amygdala and hippocampus
Change in neurotransmitters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the loss of grey matter in the pathophysiology of SZ:

A

Nº neurons unchanged (not neurodegenerative disease)
Synaptic connections- size of dendritic tree so less connections:
-increase dendritic pruning, means less connections
-many susceptibility genes involved in synaptic maintenance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe a decreased white matter volume in the pathophysiology of SZ:

A

Decrease in number of oligodendrocytes (cells which make myelin sheath)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the function of the dorsolateral pre-frontal cortex?

A

Decision making, motivational drive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the function of the ventromedial prefrontal cortex?

A

Emotional function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Describe pharmacological evidence for the dopamine hypothesis:

A

Drugs that cause DA release/ increase in synaptic conc (e.g amphetamine, cocaine) can cause psychosis
Drugs that deplete DA (e.g reserpine) decreases psychosis
D2 agonists (e.g bromocriptine) exacerbate sz
A SE of dopaminergic drugs is hallucinations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What receptors do all antipsychotics block and what does this mean?

A

All block D2 receptors
Decrease psychotic (+ve) symptoms
Correlation between clinical potency and affinity of antipsychotic drugs for the D2 receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is psychosis in sz due to?

A

Over activity of dopaminergic neurons in the mesolimbic pathway causing the +ve symptoms of sz

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Describe the dopamine hypothesis:

A

Increase conc of dopamine have been found in the presynaptic terminals of DA neurons in the mesolimbic pathway
Increase release of DA from dopaminergic neurons in mesolimbic pathway
Release of DA is greater during periods of psychosis compared to periods of remission

22
Q

What is the cause of the -ve symptoms of sz according to the dopamine hypothesis?

A

Decreased activity in the mesocortical pathway, which contributes to the -ve symptoms

23
Q

Name the dopamine pathways:

A

Mesolimbic pathway
Mesocortical pathway
Nigrostriatial pathway
Tuberohypophyseal

24
Q

Describe the mesolimbic pathway:

A

VTA (ventral tegmental area) to limbic areas, notably to nucleus accumbens (hippocampus, amygdala)
Behavioural- reward pathways (addiction problems)

25
Q

Describe the mesocortical pathway:

A

VTA to frontal cortex
Cognition and thought

26
Q

Describe the nigrostriatial pathway:

A

Cell bodies in substantia nigra (midbrain) projecting
Control of movement

27
Q

Describe the tuberohypophseal pathway:

A

Hypothalamus to pituitary
Control of secretion
DA inhibits prolactin secretion

28
Q

What is the glutamate hypothesis?

A

Due to decreased activity of glutamatetgic synapse in pyramidal neurones in the prefrontal cortex, decreased signalling via NMDAr
Can explain all types of symptoms of SZ
Can explain the changes in DA that occur in the mesolimbic and mesocortical pathways

29
Q

How can the glutamate hypothesis explain the changes in DA that occur?

A

Both downstream of the pyramidal neurons in the pre-frontal cortex
Decrease signalling via NMDAr causes downstream increased activity in the mesolimbic pathway, but decreased activity in the mesocortical pathway
Therefore fundamental NT imbalance is glutamate rather than dopamine

30
Q

Describe the evidence for the glutamate hypothesis:

A

NMDA antagonists (e.g phencyclidine, ketamine) are psychomimetic, also mimic -ve and cog symptoms of sz
Observed structural changes to the glutmainreigc pyramidal neurons in the pre frontal cortex- size and complexity of dendritic fields are decreased
Changes in all glutamate r and VGLUT1 have been reported in post mortem sz pts, but results are inconsistent in expression
Genes related to glutamergic transmission are associated with risk of sz

31
Q

What are the susceptibility genes for sz involved in?

A

Neuronal development
Synaptic formation, maintenance, structure and function

32
Q

Name examples of susceptibility genes for sz:

A

GRIN2A (NMDAr subunit) and GRIA3 (AMPAr subunit)
DAAO and DAoA (D a.a oxidise/ activator)- D serine important mod at NMDAr
CACNA1G (VGCa channel a subunit-sig at glutamaterigc synapse)

33
Q

Name the two classes of antipsychotics:

A

First gen (FGA’s) aka typical or conventional
Second gen (SGA’s) aka atypical or non-conventional

34
Q

Name examples of first gen antipsychotics:

A

Chlorpromazine (a phenothiazine) and haloperidol

35
Q

Name examples of second gen antipsychotics:

A

Clozapine
Risperidone
Olanzapine
Quetipaine

36
Q

Describe the pharmacology of antipsychotics:

A

Activity is primarily due to blocking D2r in the mesolimbic pathway
Clinical efficacy at 80% occupancy of D2r in this pathway (although there are exceptions e.g clozapine)
Also block dopamine receptors in other dopaminergic synapses which lead to SEs

37
Q

Describe the effects antipsychotics have for blocking the nigrostriatial pathway:

A

Motor effects- leads to extrapyramidal SEs- affects basal ganglia
Acute- soon after starting treatment:
Pseudo Parkinsonism
Involuntary movement
-repetitive movement
-spasm esp in face and neck (dystonias)
Later:
Tardive dyskinesias (involuntary movement in face and limbs)

38
Q

Describe the effects antipsychotics have for blocking the tuberoinfundibulnar pathway:

A

Increase prolactin secretion (hyperprolactinamiea) as DA normally inhibits secretion via D2r:
-breast development/ enlargement/ lactation/pain
-amenorrhoea/ decreased fertility in women
-loss of libido/ sexual dysfunction

39
Q

Describe the effects antipsychotics have for blocking the mesocortical pathway:

A

Blocking an already deficient pathway so can worsen -ve symptoms

40
Q

Describe the effects antipsychotics have for blocking the mesolimbic pathway:

A

Inhibition of reward pathways so can worsen negative symptoms

41
Q

How did SGA’s aim to improve clinical efficacy and SE profile?

A

Antagonist activity at 5HT2Ar e.g clozapine, olanzapine
Improving selectivity for D2 over D1r e.g risperidone
Improving selectivity for D2r over all receptors e.g sulpuride
Rapid dissociation from D2r e.g quetiapine
Partial agonist at D2r e.g aripirazole
Action at muscarinic receptors

42
Q

What is the SGA’s having antagonistic activity at the 5HT2Ar?

A

Increase release of DA in striatum
5HT increases prolactin secretion so therefor antagonist inhibits secretion
Also proposed to increase glutamate release in the cortical pyramidal cells- help all symptoms

43
Q

What is the effect of SGA’s having rapid dissociation from the D2r?

A

Antagonism not be enough for EPSE’s- downstream effects

44
Q

What is the effect of SGA’s being a partial agonist at D2r?

A

Stim D2r at much lower level than agonist
So antagonist activity so not totally shutting down pathway- fine balance

45
Q

What is the effect of SGA’s action at muscarinic receptors?

A

Ach unopposed if decreased DA so PD symptoms

46
Q

What side effects will antipsychotics cause if they have a1 antagonism?

A

Causes post hypotension, plus DA antagonism causes hypotension

47
Q

What side effects will antipsychotics cause if they have H1 antagonism?

A

Contributes to sedation caused by these drugs

48
Q

Name other SEs of antipsychotics:

A

Some 1st gen- neuroleptic malignant syndrome (rare but fatal)- muscle rigidity, confusion, high temp
Metabolic syndrome
Prolongued QT interval- arrhythmia
Neurotpenia and agranulocytosis (clozapine- must monitor WBC)

49
Q

Describe the metabolic syndrome SE of antipsychotics:

A

Weight gain (can be 2kg in 2 weeks)
Insulin resistance
Hyperlipidaemia
Can lead to T2D (also more common in pts with sz) and increased risk of CVD
Mechanism unknown (5HTr?, H1r?) but more frequent with SGA’s

50
Q

Name some potential antipsychotic targets:

A

NMDA and AMPA allosteric modulators- enhance activity
mGLUr
mGlur/5HT2r heterodimer

51
Q

Describe how NMDA and AMPA allosteric modulators would work:

A

Agonists at the NMDA glycine site could enhance activity
GlyT inhibitors were not found to be effective in clinical trials

MPharm Y3S2 (22 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions